{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:36:16Z","timestamp":1793331376010,"version":"4.5.0"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T00:00:00Z","timestamp":1734048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Comprehensive Support Project for Oncology Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Osimertinib is effective in patients with epidermal growth factor receptor (EGFR) mutation-positive nonsmall cell lung cancer (NSCLC). However, some patients require osimertinib dose reduction because of adverse events. This study assessed the characteristics of osimertinib dose reduction and compared the efficacies of reduced-dose and regular-dose osimertinib.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This multicenter, prospective, observational study enrolled patients with EGFR mutation-positive NSCLC who started first-line osimertinib treatment between September 2018 and August 2020. We categorized the patients into two groups: those who required dose reduction during osimertinib treatment (reduction group) and those who continued osimertinib treatment at a dose of 80\u00a0mg\/day without dose reduction (nonreduction group). The primary endpoints were progression-free survival (PFS) and pattern of progression, whereas the secondary endpoints included overall survival (OS) and reasons for osimertinib dose reduction.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the included 575 patients, 175 (30.4%) and 400 (69.6%) were classified into the reduction and nonreduction groups, respectively. PFS was significantly better in the reduction group than in the nonreduction group [hazard ratio (HR)\u00a0=\u00a00.67, 95% confidence interval (CI)\u00a0=\u00a00.54\u20130.84; P\u00a0&amp;lt;0.001]. Meanwhile, the pattern of progression and OS (HR\u00a0=\u00a00.82, 95% CI\u00a0=\u00a00.62\u20131.08; P\u00a0= 0.15\u00a0) did not differ significantly between the two groups. Osimertinib was reduced due to physician's decision or adverse events and the main reasons were rash and gastrointestinal symptoms such as nausea and diarrhea.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Many patients require osimertinib dose reduction due to adverse events, but this process does not adversely affect the drug efficacy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyae173","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T18:40:41Z","timestamp":1734201641000},"page":"261-268","source":"Crossref","is-referenced-by-count":7,"title":["Outcome of osimertinib-treated patients with epidermal growth factor receptor mutation-positive nonsmall cell lung cancer requiring dose reduction: a secondary analysis of the Reiwa study"],"prefix":"10.1093","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1438-4880","authenticated-orcid":false,"given":"Nobuyasu","family":"Awano","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Medical Center , 4-1-22 Hiroo, Shibuya-ku, Tokyo 150-8935 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Yoh","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, National Cancer Center Hospital East , 6-5-1 Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Usui","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, NTT Medical Center Tokyo , 5-9-22 Higashigotanda, Shinagawa-ku, Tokyo 141-8625 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital , 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Kishi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Toho University Omori Medical Center , 6-11-1 Omorinishi, Ota-ku, Tokyo 143-8541 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Naka","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine , 30-1 Otaniguchiuemachi, Itabashi-ku, Tokyo 173-8610 ,","place":["Japan"]},{"name":"Department of Respiratory Medicine, National Center for Global Health and Medicine , 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8420-5606","authenticated-orcid":false,"given":"Kageaki","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital , 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Tamano","sequence":"additional","affiliation":[{"name":"Biostatistics and Bioinformatics Course, Graduate School of Interdisciplinary Information Studies, The University of Tokyo , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8654 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Uemura","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, The Interfaculty Initiative in Information Studies, The University of Tokyo , 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8654,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Kunitoh","sequence":"additional","affiliation":[{"name":"Department of Chemotherapy, Japanese Red Cross Medical Center , 4-1-22 Hiroo, Shibuya-ku, Tokyo 150-8935 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,13]]},"reference":[{"key":"2025030608515907500_ref1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1200\/JCO.2015.62.0096","article-title":"Cancer genomics: Diversity and disparity across ethnicity and geography","volume":"34","author":"Tan","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025030608515907500_ref2","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"2025030608515907500_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2024.100720","article-title":"The whole picture of first-line Osimertinib for EGFR mutation-positive advanced non-small-cell lung cancer: Real-world efficacy, safety, progression pattern, and posttreatment therapy (Reiwa study)","volume":"5","author":"Watanabe","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"2025030608515907500_ref4","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3332\/ecancer.2019.970","article-title":"Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure","volume":"13","author":"Harada","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"2025030608515907500_ref5","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2147\/OTT.S315385","article-title":"Pancytopenia during osimertinib treatment in a patient with EGFR-mutated non-small cell lung cancer","volume":"15","author":"Di Marino","year":"2022","journal-title":"Onco Targets Ther"},{"key":"2025030608515907500_ref6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s10637-024-01432-4","article-title":"Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer","volume":"42","author":"Hori","year":"2024","journal-title":"Invest New Drugs"},{"key":"2025030608515907500_ref7","doi-asserted-by":"publisher","first-page":"23140","DOI":"10.1038\/s41598-021-02561-z","article-title":"First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: A retrospective multicenter study (HOT2002)","volume":"11","author":"Yamamoto","year":"2021","journal-title":"Sci Rep"},{"key":"2025030608515907500_ref8","doi-asserted-by":"publisher","first-page":"e046451","DOI":"10.1136\/bmjopen-2020-046451","article-title":"Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): Study protocol of a multicentre, real-world observational study","volume":"12","author":"Watanabe","year":"2022","journal-title":"BMJ Open"},{"key":"2025030608515907500_ref9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025030608515907500_ref10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cllc.2013.10.001","article-title":"Acquired resistance to targeted therapies against oncogene-driven non-small-cell lung cancer: Approach to subtyping progressive disease and clinical implications","volume":"15","author":"Gandara","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"2025030608515907500_ref11","doi-asserted-by":"publisher","first-page":"e000214","DOI":"10.1136\/esmoopen-2017-000214","article-title":"Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: An observational study","volume":"2","author":"Goto","year":"2017","journal-title":"ESMO Open"},{"key":"2025030608515907500_ref12","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/tri.13081","article-title":"An unjustified benefit: Immortal time bias in the analysis of time-dependent events","volume":"31","author":"Gleiss","year":"2018","journal-title":"Transpl Int"},{"key":"2025030608515907500_ref13","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1093\/jjco\/hyac034","article-title":"Overview of the ethical guidelines for medical and biological research involving human subjects in Japan","volume":"52","author":"Eba","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"2025030608515907500_ref14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/jjco\/hyy179","article-title":"Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset","volume":"49","author":"Ohe","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"2025030608515907500_ref15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"key":"2025030608515907500_ref16","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s10637-021-01195-2","article-title":"First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study","volume":"40","author":"Igawa","year":"2022","journal-title":"Invest New Drugs"},{"key":"2025030608515907500_ref17","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.23.00377","article-title":"Importance of low- and moderate-grade adverse events in patients\u2019 treatment experience and treatment discontinuation: An analysis of the E1912 trial","volume":"42","author":"O\u2019Connell","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025030608515907500_ref18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejca.2021.09.041","article-title":"Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation\u2013positive non\u2013small-cell lung cancer in a real-world setting (OSI-FACT)","volume":"159","author":"Sakata","year":"2021","journal-title":"Eur J Cancer"},{"key":"2025030608515907500_ref19","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor\u2013resistant non\u2013small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N Engl J Med"},{"key":"2025030608515907500_ref20","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/jjco\/hyae032","article-title":"Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70 years or older (\u201cMONEY\u201d trial)","volume":"54","author":"Tsukita","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"2025030608515907500_ref21","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","article-title":"CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"36","author":"Reungwetwattana","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025030608515907500_ref22","doi-asserted-by":"publisher","first-page":"17731","DOI":"10.1002\/cam4.6393","article-title":"Osimertinib early dose reduction as a risk to brain metastasis control in EGFR-mutant non-small cell lung cancer","volume":"12","author":"Tozuka","year":"2023","journal-title":"Cancer Med"},{"key":"2025030608515907500_ref23","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.21873\/invivo.11871","article-title":"Comparison of the efficacy of EGFR tyrosine kinase inhibitors erlotinib and low-dose osimertinib on a PC-9-GFP EGFR mutant non-small-cell lung cancer growing in the brain of nude mice","volume":"34","author":"Katsuya","year":"2020","journal-title":"In Vivo"},{"key":"2025030608515907500_ref24","doi-asserted-by":"publisher","first-page":"100656","DOI":"10.1016\/j.jtocrr.2024.100656","article-title":"Osimertinib plasma trough concentration in relation to brain metastases development in patients with advanced EGFR-mutated NSCLC","volume":"5","author":"Gulikers","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"2025030608515907500_ref25","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: The BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025030608515907500_ref26","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1200\/JCO.24.00708","article-title":"Phase II efficacy and safety of 80 mg osimertinib in patients with leptomeningeal metastases associated with epidermal growth factor receptor mutation-positive non-small cell lung cancer (BLOSSOM)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/3\/261\/61142549\/hyae173.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/55\/3\/261\/61142549\/hyae173.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T08:52:09Z","timestamp":1741251129000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/55\/3\/261\/7923117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,13]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,12,13]]},"published-print":{"date-parts":[[2025,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyae173","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,12,13]]}}}